Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Mon Mar 31 20:33:22 GMT 2025
by
admin
on
Mon Mar 31 20:33:22 GMT 2025
|
| Protein Type | COAGULATION FACTOR |
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
3Z6S89TXPW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Related Record | Type |
|---|
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
225806
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
FDA ORPHAN DRUG |
65392
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
LOINC |
13050-0
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
LOINC |
6008-7
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
NDF-RT |
N0000175980
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
LOINC |
49639-8
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
LOINC |
4671-4
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
FDA ORPHAN DRUG |
305310
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
FDA ORPHAN DRUG |
65292
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
WHO-ATC |
B01AD12
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
LOINC |
6007-9
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
FDA ORPHAN DRUG |
65192
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
WHO-VATC |
QB01AD12
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
||
|
LOINC |
6006-1
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
N0000168402
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY | Enzyme Precursors [Chemical/Ingredient] | ||
|
N0000008556
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY | Decreased Coagulation Factor Activity [PE] | ||
|
3Z6S89TXPW
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY | |||
|
D011486
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY | |||
|
DB11312
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY | |||
|
3Z6S89TXPW
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY | |||
|
SUB12567MIG
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY | |||
|
60202-16-6
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY | |||
|
8834
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY | |||
|
100000092007
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY | |||
|
C87607
Created by
admin on Mon Mar 31 20:33:22 GMT 2025 , Edited by admin on Mon Mar 31 20:33:22 GMT 2025
|
PRIMARY |
| Glycosylation Type | MAMMALIAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_139 |
| N | 1_290 |
| N | 1_355 |
| N | 1_371 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SUB_CONCEPT->SUBSTANCE | |||
|
ACTIVATOR -> TARGET |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| GAMMA-CARBOXYGLUTAMIC ACID | [1_31] [1_48] [1_49] [1_56] [1_58] [1_61] [1_62] [1_67] [1_68] [1_71] | .GAMMA.-CARBOXYGLUTAMIC ACID | 16FQV4RZKL |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:FORMULA | CHEMICAL |
|